AETHLON MEDICAL INC. news, videos and press releases
For more news please use our advanced search feature.
AETHLON MEDICAL INC. - More news...
AETHLON MEDICAL INC. - More news...
- Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025
- Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial
- Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu
- Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update
- Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia
- Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024
- Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit
- Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India
- Aethlon Medical to Present at Virtual Investor Conferences in September
- Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial
- Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys
- Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update
- Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial
- Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024
- Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update
- Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024
- Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial
- Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies
- Aethlon Medical Announces Pricing of $4.7 Million Public Offering
- Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma
- Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices
- Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update
- Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024
- Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update
- Aethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating Officer
- Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023
- Aethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifier® in Oncology
- Aethlon Announces Reverse Stock Split
- Aethlon Medical to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Aethlon Medical Announces Fiscal First Quarter Financial Results and Provides Corporate Update
